The U.S. Supreme Court decided today to consider the patent-eligibility of isolated DNA sequences by reviewing the Federal Circuit’s decision – Ass’n for Molecular Pathology v. Myriad Genetics, Inc., No. 2010-1406 (Fed. Cir. 2012).